dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Yang, James Chih-Hsin |
dc.contributor.author | Jänne, Pasi A. |
dc.contributor.author | Ramalingam, Suresh |
dc.contributor.author | Kim, Tae Min |
dc.contributor.author | Riely, Gregory |
dc.contributor.author | FELIP, ENRIQUETA |
dc.contributor.author | Zhou, Caicun |
dc.date.accessioned | 2023-05-12T07:55:16Z |
dc.date.available | 2023-05-12T07:55:16Z |
dc.date.issued | 2023 |
dc.identifier.citation | Yang JCH, Zhou C, Jänne PA, Ramalingam SS, Kim TM, Riely GJ, et al. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer. Expert Rev Anticancer Ther. 2023;23(1):95–106. |
dc.identifier.issn | 1744-8328 |
dc.identifier.uri | https://hdl.handle.net/11351/9519 |
dc.description | Carcinoma; Càncer de pulmó de cèl·lules no petites; Seguretat del pacient |
dc.description.sponsorship | The paper received funding from Takeda Development Center Americas Inc., Lexington, MA, USA. |
dc.language.iso | eng |
dc.publisher | Taylor & Francis |
dc.relation.ispartofseries | Expert Review of Anticancer Therapy;23(1) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Efectes secundaris |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /adverse effects |
dc.title | Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1080/14737140.2023.2157815 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1080/14737140.2023.2157815 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Yang JC] Graduate Institute of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan. [Zhou C] Shanghai Pulmonary Hospital, Shanghai, China. [Jänne PA] Dana-Farber Cancer Institute, Boston, MA, USA. [Ramalingam SS] School of Medicine, Emory University, Atlanta, GA, USA. [Kim TM] Seoul National University Hospital, Seoul, South Korea. [Riely GJ] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 36537204 |
dc.identifier.wos | 000904702000001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |